Meng Zou
PHD candidate
Academy of Mathematics & Systems Science, Chinese Academy of Sciences
Address : Zhongguancun East Road No.55, , HaiDian District, Beijing 100080, China
Tel : 15501271045
Email : zoumeng@amss.ac.cn
Background
2007,9~2011,7 -- B.S.
School of Mathematical Sciences, DaLian University of Technology
2011,9~ now -- Ph.D.
Applied Mathematics, Academy of Mathematics and Systems Science, Chinese Academy of Science
Hobbies
- Reading, Writing
- Badminton, swimming, jogging
Honors
- The Presidential Outstanding Research Scholarship of Academy of Mathematics and Systems Science, Chinese Academy of Science, 2014
- Merit student of Chinese Academy of Science, 2011-2012
- The Presidential Outstanding Graduates of School of Mathematical Sciences, DaLian University of Technology, 2011
- The Presidential Second-Class Scholarship of School of Mathematical Sciences, DaLian University of Technology, 2007-2010.
Research Interests
- Cancer Genomics and Next Generation Sequencing
- Early Detection and Precision Medicine
- Optimization and Algorithm Design
- Machine Learning and Data Mining
Publications
~1) Meng Zou, Zhaoqi Liu, Xiang-Sun Zhang and Yong Wang.
NCC-AUC:an AUC optimization method to identify multi-biomarker panel for cancer prognosis from genomic and clinical data.
Bioinformatics (2015).
~2) Meng Zou, Peng-Jun Zhang, Xin-Yu Wen, Luonan Chen, Ya-Ping Tian, Yong Wang.
A novel mixed integer programming for multi-biomarker panel identification by distinguishing malignant from benign colorectal tumors.
Methods, 2015, 83: 3-17.
~3) Pengjun Zhang, Meng Zou (co-first), Xinyu Wen, Feng Gu, Juan Li, Gaixia Liu, Jingxiao Dong, Xinxin Deng, Jing Gao, Xiaolong Li, Xingwang Jia, Zhennan Dong, Luonan Chen, Yong Wang and Yaping Tian.
Development of serum parameters panels for the early detection of pancreatic cancer.
International Journal of Cancer, 2014, 134(11): 2646-2655.
~4) Wenjun Mou, Zhaoqi Liu, Yuan Luo, Meng Zou, Chao Ren, Chunyan Zhang, Xinyu Wen, Yong Wang, Yaping Tian.
Development and cross-validation of prognostic models to assess the treatment effect of cisplatin/pemetrexed chemotherapy in lung adenocarcinoma patients.
Medical Oncology, 2014, 31(9): 1-9.
